In recent years, great advances in new therapeutic strategies for the treatment of AD emerged: monoclonal antibodies directed against interleukins involved in disease pathogenesis or their receptors, and small molecule drugs inhibiting JAK-STAT signaling pathways have been developed. Here, SOAT1 is linked to Alzheimer disease.